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C
ombination nucleos(t)ide analogs (NUCs) had
been advocated as the initial treatment of
chronic hepatitis B when lamivudine and
adefovir dipivoxil (ADV) were the only approved NUCs
for hepatitis B. These drugs had weak antiviral activity
and/or low barrier to resistance with rates of genotypic
resistance of 70% and 29%, respectively, after 5 years of
continuous treatment.1,2 Borrowing from lessons
learned in development of treatment for human
immunodeficiency virus infection, virologists warned
that a combination of NUCs with no cross-resistance
would be necessary to maintain long-term suppression
of hepatitis B virus (HBV) replication.
In the past 7 years, three additional NUCs have
been approved for hepatitis B. Of these, entecavir
(ETV) and tenofovir disoproxil fumarate (TDF) have
been shown to have a very high barrier to resistance.
Phase III clinical trials found that the incidence of
genotypic resistance was 1.2% and 0% after 5 years of
ETV and TDF monotherapy in NUC-naı¨ve patients,
respectively.3,4 Among hepatitis B e antigen (HBeAg)-
positive patients, 94% of ETV-treated patients had
HBV DNA <300 copies/mL and 97% of TDF-
treated patients had HBV DNA <400 copies/mL at
Year 5.4,5 Although the design of both trials left room
for doubt, these data showed that monotherapy with
ETV or TDF can maintain viral suppression in the
vast majority of patients with chronic hepatitis B for
at least 5 years.
In the phase III ETV trial, only 183 of 354 patients
were enrolled in the roll-over study, some patients had
a short gap in treatment between Years 2 and 3, a
small number of patients received a combination of
lamivudine and ETV for a short duration, and all
patients received a higher dose of ETV (1.0 mg) from
Year 3 onward.5 Nevertheless, other studies in which
ETV 0.5 mg was administered continuously confirmed
that >90% of patients had undetectable HBV DNA
and 0%-1% had genotypic resistance after 3-4 years of
treatment (Fig. 1).6-10 In the phase III TDF trial,
patients with confirmed HBV DNA 400 copies/mL
on or after Week 72 were eligible to add emtricitabine
(FTC) to TDF and 34 of 51 eligible patients did
so.4,11 A multicenter field study of TDF monotherapy
in Italy confirmed that HBV DNA was undetectable
in 95% HBeAg-positive and in 98% HBeAg-negative
patients at Year 3 in the absence of FTC rescue.12
These additional studies support the optimism that
monotherapy with ETV or TDF would be sufficient
for the vast majority of NUC-naı¨ve patients with
chronic hepatitis B. A lingering question is whether
this optimism can be applied to patients with high
baseline viral load.
In this issue of Hepatology, Gordon et al.13 reported
the results of a subgroup analysis of the phase III TDF
trial. Eligible patients (HBeAg-positive and HBeAg-nega-
tive) were randomized to receive TDF 300 mg daily or
ADV 10 mg daily for 48 weeks and then open-label
TDF for an additional 192 weeks. Of 641 patients en-
rolled in the trial, 129 (118 HBeAg-positive) had high
baseline viral load (HVL) defined as HBV DNA 9
log10 copies/mL (8.24 log10 IU/mL). At Week 240
(Year 5), 96.1% of HVL and 98.7% of non-HVL
patients on treatment achieved HBV DNA <400 copies/
mL. Both groups had similar rates of histologic regression
between baseline and Week 240. Patients with HVL gen-
erally took longer to achieve HBV DNA <400 copies/
mL but had caught up with the non-HVL patients by
Week 96. The authors stated that no patient with baseline
HVL had persistent viremia at Week 240 or amino acid
substitutions associated with TDF resistance.
These results are remarkable and suggest that mono-
therapy with a potent NUC that has a high barrier to
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resistance such as TDF is sufficient in maintaining vi-
ral suppression during long-term treatment even in
patients with HVL. However, the results should be
interpreted with caution. Persistent viremia in this
study was defined as never having HBV DNA <400
copies/mL and this endpoint was only reported on
patients who remained on treatment at Week 240.
Thus, patients with HBV DNA <400 copies/mL at a
single timepoint and higher levels of HBV DNA sub-
sequently would not be considered to have persistent
viremia and those who were no longer on treatment at
Week 240 were not counted. Of the 129 patients with
baseline HVL, 46 discontinued the study before Week
240 of whom 28 had HBV DNA <400 copies/mL at
the last visit. In the remaining 83 patients, 73 had
HBV DNA <400 copies/mL, three had HBV DNA
400 copies/mL, and HBV DNA of the other seven
were unknown at Week 240. Thus, based on intention
to treat analysis, only 56.6% (73/129) patients had
HBV DNA <400 copies/mL at Week 240. If the last
result was carried forward, 78.3% (101/129) patients
had HBV DNA <400 copies/mL. By contrast, HBV
DNA <400 copies/mL at Week 240 was achieved in
76.0% (389/512) non-HVL patients by intention to
treat analysis and in 91.0% (466/512) if the last result
was carried forward. Furthermore, 35 HVL patients
were eligible to add FTC between Week 72 and 240
and 28 eligible plus one noneligible patient had FTC
added. Adding FTC did not appear to affect HBV
DNA outcomes, with 66% (19/29) on FTC/TDF and
86% (6/7) on TDF having HBV DNA <400 copies/
mL at Week 240 or last visit. The difference was not
statistically significant but this may be related to the
small number of patients. HBV DNA levels of the 11
patients with HBV DNA 400 copies/mL were not
provided.
That patients with HVL take longer to achieve viro-
logic response had also been observed by other investi-
gators. Yuen et al.6 studied 222 NUC-naı¨ve patients
and found that 100% and 76.5% of patients with base-
line HBV DNA < and 8 log10 copies/mL, respec-
tively, had undetectable HBV DNA at Year 3 of ETV
therapy. The only patient in whom ETV resistance was
detected had baseline HBV DNA 8.1 log10 copies/mL.
In a randomized trial comparing ETV monotherapy
versus combination of ETV plus TDF in NUC naı¨ve
patients, Lok et al.14 showed that 76.4% and 83.2%
patients, respectively, achieved the primary endpoint of
HBV DNA <50 IU/mL (300 copies/mL) at Week
96 (P ¼ 0.088). However, a significant difference was
observed at Week 96 in HBeAg-positive patients with
HVL (defined as HBV DNA 8 log10 IU/mL), 62.0%
versus 78.8% (P ¼ 0.018) and in the entire cohort at
Week 48, 70.3% versus 80.2% (P ¼ 0.026).
A key question is whether more rapid suppression
of HBV replication is clinically relevant. Rapid viral
suppression is important in preventing antiviral drug
resistance when NUCs with a low barrier to resistance
such as lamivudine or telbivudine are used.15,16 The
impact seems to be small with ETV or TDF. Rapid vi-
ral suppression may be important in patients with
acute liver failure, severe exacerbation of chronic hepa-
titis B, or decompensated cirrhosis but there is no evi-
dence to support this notion. Rapid viral suppression
may also be important in patients with high levels of
HBV DNA who are about to start immunosuppressive
therapy; however, data to substantiate this are not
available.
In summary, existing data support that initial treat-
ment with combination NUCs is not necessary for the
Fig. 1. Virologic response after 2-5 years of treatment with enteca-
vir (ETV) or tenofovir disoproxil fumarate (TDF) monotherapy or combi-
nation of ETV plus TDF in nucleos(t)ide-naı¨ve patients with chronic
hepatitis B, (A) HBeAgþ and HBeAg patients, and (B) patients with
high versus not high viral load (HVL). Different definitions were used
for virologic response and high viral load in different studies. LFU ¼
subset of patients with long-term follow-up; KM ¼ Kaplan-Meier prob-
ability of response; PP ¼ per protocol analysis of patients with data
at that timepoint; ITT ¼ intention to treat analysis with missing data
counted as failure; LCF ¼ last result carried forward.
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vast majority of patients with chronic hepatitis B when
ETV or TDF is used, and while combination therapy
may accelerate viral suppression in patients with high
baseline viral load, in most instances the marginal clin-
ical benefit does not justify the added cost.
ANNA SUK-FONG LOK, M.D.
University of Michigan
Ann Arbor, MI
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